COST action CA21151 “HAPLO-iPS: GENERATION OF HUMAN INDUCED PLURIPOTENT STEM CELLS FROM HAPLO-SELECTED CORD BLOOD SAMPLES” was promoted in Sofia, Bulgaria on 5th November 2022. Workshop held in Sheraton Hotel Balkan Sofia aimed at consolidation of national research infrastructure capacity in translational medicine and was organized under the patronage of INFRAACT of NRRI 2020-2027.
The event aimed to reinforce the interest of the scientific community around topics of personalized medicine, latest developments in the area of induced pluripotent stem cells, challenges and perspectives for translation of this research, with focus on national developments. The audience of academic researchers and clinicians, as well as different stakeholders from the public and private sector attended to learn about the latest developments in the ATMP Platform and current initiatives in support of the development of next generation cell and gene therapies, presented by David Morrow, Senior Scientific Program Manager – ATMP and VIIM Platforms of EATRIS-ERIC. The new COST action CA21151 “HAPLO-iPS” was presented by Begoña Aran, PhD and Ester Rodriguez, PhD from IDIBELL (Bellvitge Biomedical Research Institute) and P-CMR[C] (Program for Clinical Translation of Regenerative Medicine in Catalonia). Opportunities for national collaborations and perspectives of new partnerships were discussed.
